Vertex Pharmaceuticals Incorporated Common Stock (VRTX)
Stock · NASDAQ · Health Care
$499.78as of 10/16/2026
Price chart
Active signals
VRTX Signal Track Record
How signals performed across all stocks →What VRTX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakout | 34 | -2.4% | 41% | August 7, 2026 |
| Volume Spike | 32 | +3.7% | 66% | September 18, 2026 |
| 200-Day Moving Average TouchActive now | 16 | +5.0% | 69% | June 1, 2026 |
| Bollinger Band Breakdown | 15 | +2.3% | 60% | April 27, 2026 |
| Any 20-session window (baseline) | +1.5% | 59% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About VRTX
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 6,400
- Website
- www.vrtx.com/
Fundamentals
- 1-day range
- $507.21$517.68
- Market cap
- $122.68B
- P/E (trailing)
- 29.32
- P/E (forward)
- 25.29
- EPS (trailing)
- $17.19
- Dividend yield
- —
- Beta
- 0.28
- Avg. volume
- 1.16M
How Vertex Pharmaceuticals Incorporated Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 13, 2026 · via SEC EDGAR / Finnhub
Forecasts
28 analyst ratings
Vertex Pharmaceuticals Incorporated Common Stock Competitors
Chosen by industry and closest market cap.
- VRTXVertex Pharmaceuticals Incorporated Common Stock$499.74▼ 1.77%Market cap $122.68BP/E 29.32$403.16$560.25
- BMYBristol-Myers Squibb Company Common Stock$59.75▼ 1.35%Market cap $131.04BP/E 13.53$42.52$68.64
- GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)$49.51▲ 1.00%Market cap $105.65BP/E 15.09$1,592$2,282
- SNYSanofi ADS$40.61▲ 0.79%Market cap $104.60BP/E 21.77$69.75$91.15
- PFEPfizer Inc. Common Stock$29.58▲ 0.48%Market cap $149.33BP/E 39.08$23.62$29.49
- REGNRegeneron Pharmaceuticals Inc. Common Stock$790.74▼ 0.70%Market cap $79.49BP/E 19.00$564$859.34
- ABTAbbott Laboratories Common Stock$104.89▲ 0.20%Market cap $186.81BP/E 33.41$81.97$132.03
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Incorporated Common Stock | $122.68B | 29.32 | $499.74 | ▼ 1.77% | $403.16$560.25 |
| BMY Bristol-Myers Squibb Company Common Stock | $131.04B | 13.53 | $59.75 | ▼ 1.35% | $42.52$68.64 |
| GSK GSK plc American Depositary Shares (Each representing two Ordinary Shares) | $105.65B | 15.09 | $49.51 | ▲ 1.00% | $1,592$2,282 |
| SNY Sanofi ADS | $104.60B | 21.77 | $40.61 | ▲ 0.79% | $69.75$91.15 |
| PFE Pfizer Inc. Common Stock | $149.33B | 39.08 | $29.58 | ▲ 0.48% | $23.62$29.49 |
| REGN Regeneron Pharmaceuticals Inc. Common Stock | $79.49B | 19.00 | $790.74 | ▼ 0.70% | $564$859.34 |
| ABT Abbott Laboratories Common Stock | $186.81B | 33.41 | $104.89 | ▲ 0.20% | $81.97$132.03 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to KnowYahoo · 10/9/2026
- Vertex Presents Study Reporting ALYFTREK Data Shows Pancreatic Function Recovery In Some Children Ages 2–5 With Cystic Fibrosisbenzinga · 10/9/2026
- Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis ConferenceYahoo · 10/9/2026
- Is Vertex Stock Worth More Than Its Competitors?Yahoo · 10/9/2026
- Vertex Presents Study Reporting ALYFTREK Data Shows Pancreatic Function Recovery In Some Children Ages 2–5 With Cystic FibrosisBenzinga · 10/9/2026
- If You Invested $100 In Vertex Pharmaceuticals Stock 5 Years Ago, You Would Have This Much TodayBenzinga · 10/9/2026
- For the final 10% of cystic fibrosis patients, the breakthrough still hasn't comeCNBC · 10/9/2026
- Why Pacira BioSciences Stock Is Having Its Best Day Ever After $1.7 Billion Viatris AcquisitionYahoo · 10/8/2026
- Andrew Hill Investment Fund Sees More Growth Ahead for Vertex (VRTX): Here’s WhyYahoo · 10/8/2026
Insider Activity
Insider Actions →- van Grunsven Jasper · September 8, 2026 · Grant8.7K
- Kristen Ambrose · August 28, 2026 · Grant5.0K
- SACHS BRUCE I · August 27, 2026 · Gift6.0K
- Ourania Tatsis · July 21, 2026 · Grant8.3K
- Amit Sachdev · July 21, 2026 · Grant8.3K
- Alan M. Garber · July 15, 2026 · Grant32 @ $475.28
- SACHS BRUCE I · July 15, 2026 · Grant100 @ $475.28
- Duncan McKechnie · July 2, 2026 · Sale1.5K @ $519
- Ourania Tatsis · July 2, 2026 · Sale1.5K @ $524.99
- Joy Liu · July 1, 2026 · Sale828 @ $502.71
- Carmen Bozic · June 18, 2026 · Sale1.0K @ $462.17
- Carmen Bozic · June 5, 2026 · Sale1.7K @ $450
- Joy Liu · June 1, 2026 · Sale828 @ $439.91
- Carmen Bozic · May 29, 2026 · Sale2.0K @ $450
- Mark E. Bunnage · May 15, 2026 · Sale33 @ $453.45
Institutional Ownership
March 31, 2026
- Total shares held
- 220.10M
- Total value held
- $95.91B
- Institutional holders
- 1663
- Unknown25.37M
- Unknown23.97M
- Unknown21.13M
- Unknown16.51M
- Unknown11.73M
- Unknown6.14M
- Unknown5.13M
- Unknown4.00M
- Unknown3.91M
- Unknown3.21M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Vertex Highlights Sickle Cell Gene Therapy and Hormone Disorder Expansion
Vertex Pharmaceuticals is advancing a gene therapy for sickle cell disease, which could broaden its treatment portfolio but faces access challenges. The company also signals a potential new growth area in hormone disorders, moving beyond cystic fibrosis. With earnings approaching, investors are watching how these developments affect the company’s outlook. The stock has risen above the market recently, reflecting positive sentiment.
Vertex Highlights Sickle Cell Gene Therapy and Hormone Disorder Expansion. Vertex Pharmaceuticals is advancing a gene therapy for sickle cell disease, which could broaden its treatment portfolio but faces access challenges. The company also signals a potential new growth area in hormone disorders, moving beyond cystic fibrosis. With earnings approaching, investors are watching how these developments affect the company’s outlook. The stock has risen above the market recently, reflecting positive sentiment.